Alexandria — Full Portfolio

Congruence is a drug discovery company that applies protein dynamics, biophysics, machine learning, and computational chemistry to model proteins in their full dynamic state and predict disease correction in silico.

AI & Machine LearningBiotechDeep Tech

Clarissa Desjardins(Founder)in

Co-investorsOrbiMedDIMENSIONBDC Thrive Venture Fund for WomenLumira Ventures

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases.

BiotechHealthtechMedical Devices

Paul F. Truex(Chairman of the Board & Chief Executive Officer)inDebra OdinkinAmy Sehnertin

Co-investorsAmzak HealthadMare BioInnovationsCTI Life Sciences Fund L.P.Lumira Ventures

Applied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need.

BiotechHealthtechNew York, US

Shoshana Shendelman(Executive Officer, Director)in

BoardLes Funtleyder(Director)

Board seatJoel S. Marcus· per SEC Form D · $20M raise · filed Nov 2019

Co-investorsEvolution VC PartnersVenrock Healthcare Capital Partners

BiotechWoburn, US

David Lucchino(Executive Officer, Director)inChristopher R. Loose(Executive Officer)

BoardRobert Langer(Director)Marc Kozin(Director)Marc Cohen(Director)Timothy Barberich(Director)

Board seatJoel S. Marcus· per SEC Form D · $42.3M raise · filed Jul 2020

Co-investorsvenBio PartnersKendall Capital Partners

Ability is a biotechnology company developing highly-selective, immune cell-modulating antibody therapeutics for patients with inflammatory diseases and cancer.

AI & Machine LearningBiotechHealthtechMontreal, CA

Giles Day(Co-founder)in

Co-investorsPage One VenturesFonds de solidarité FTQ

HealthtechLa Jolla, US

Ahmet Tutuncu, M.D., Ph.D.(Executive Officer, Director)

BoardTighe Reardon(Executive Officer)Heather Preston, M.D.(Director)Jay B. Lichter, Ph.D.(Director)Sanford Madigan, Ph.D.(Director)John Stuart Patton, Ph.D.(Director)

Co-investorsAvalon BioVenturesCorrelation Ventures

Asher Bio develops selective immunotherapy drugs that target specific immune cell types to promote beneficial effects while minimizing toxicity.

BiotechHealthtechMedical DevicesSan Francisco, US

Ivana Djuretic(Founder)inAndy Yeung(Founder)in

Co-investorsEmles Venture PartnersGoAhead VenturesMission Bay CapitalMission BiocapitalRA CapitalY Combinator+3 more

BiotechNew York, US

Huafeng Xu(Executive Officer, Director)

BoardKeith Loebner(Director)

Co-investorsChemistrySutter Hill Ventures

Clinical-stage drug-device company developing pegloprastide (AVB-620) for real-time surgical margin detection in cancer surgery.

Co-investorsTorrey Pines Investment

Durham, US

Matthew B Crisp(Executive Officer, Director)Lee Palles(Executive Officer)inNadine Carozzi(Executive Officer)Todd C Mockler(Executive Officer)Thomas Brutnell(Executive Officer)

BoardDaniel J Broderick(Director)

Co-investorsActivant CapitalFall Line CapitalGV (Google Ventures)iSelect FundMercury FundMissouri Technology Corporation+1 more

Agricultural biotechnology company using boron-based synthetic chemistry to develop next-generation fungicides.

Research Triangle Park, US

Tracy Jackson(Executive Officer)John Dombrosky(Executive Officer)

BoardJoel Marcus(Director)Kristina Burow(Director)inStephen Benkovic(Director)Paul Schimmel(Director)

Co-investorsARCH Venture PartnersBill & Melinda Gates Foundation

Bright Peak Therapeutics is a biotechnology company developing multi-functional PD-1 inhibitors for cancer immunotherapy, based on its EDC protein-engineering platform.

BiotechHealthtechSan Diego, US

Vijaya Pattabiraman(Co-founder & Chief Technology Officer)inJeffrey Bode(Scientific Co-founder)inFredrik Wiklund(Chief Executive Officer)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)

Co-investorsRA CapitalJohnson & Johnson Innovation – JJDCVersant VenturesVenrockBlackRockFidelity Investments+2 more

BiotechTucson, US

Louis Breton(Executive Officer, Director)David Baltimore, Ph.D.(Director)Bhavin Raval(Executive Officer)

BoardPeter Kolchinsky(Director)inJon Faiz Kayyem, Ph.D.(Director)Harry A. George(Director)

Co-investorsCycad Group LLCRA Capital

Combines single-cell RNA analysis technology from the Broad Institute with AI/ML models and large-scale clinical sample collection for novel drug discovery and precision medicine.

HealthtechCambridge, US

Tariq Kassum(Executive Officer, Director)inMichael Boretti(Executive Officer)Christoph Lengauer(Executive Officer, Director)

Co-investorsCatalio Capital Management, LPFast Track InitiativeCasdin CapitalGV (Google Ventures)Third Rock Ventures

BiotechCambridge, US

Christoph M. Adams(Executive Officer, Director)James McArthur(Executive Officer)

BoardDavid Mott(Director)Mette Kirstine Agger(Director)Barbara Dalton(Director)Sandip Agarwala(Director)

Co-investorsLongitude CapitalNew Enterprise Associates (NEA)Pfizer Venture Investments

Delphia Therapeutics is a biotechnology company developing cancer medicines based on its activation lethality platform, aiming to create therapies effective on their own while combating resistance to targeted therapies.

BiotechHealthtechCambridge, US

Kevin Marks(Founder)in

Co-investorsGV (Google Ventures)Nextech InvestTaiho Ventures, LLC

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.

BiotechDeep TechSouth San Francisco, US

Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)inGreg Lazar(Co-Founder & Chief Scientific Officer)inRichard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)in

BoardAlicia Levey(Director)Michael Ross(Director)

Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesDementia Discovery FundQiming HealthcareQiming Venture Partners USA

San Diego protein-sequencing company behind the ProteoCode platform; ceased operations in late 2025.

Co-investorsARCH Venture PartnersDecheng CapitalDeerfield Management CompanyGV (Google Ventures)Nan Fung Life SciencesNorthpond Ventures

Ensoma is a genomic medicine company developing a platform for in vivo engineering of hematopoietic stem cells (HSCs), combining an off-the-shelf delivery system with a gene engineering toolkit intended to treat diseases with a one-time treatment.

BiotechHealthtechMedical DevicesBoston, US

Albert Seymour(Director)

BoardKush Parmar(Executive Officer, Director)Paula Soteropoulos(Director)Stephen Knight(Director)

Co-investors5AM VenturesAju IB Invesment CorporationCatalio Capital Management, LPDelos CapitalF-Prime CapitalSolasta Ventures+7 more

BiotechSouth San Francisco, US

Aaron Tynes Hammack(Executive Officer, Director)Nicholas Conley(Executive Officer, Director)

BoardPing-Chuan Tsai(Director)

Co-investorsMatrix Capital ManagementSv Tech Ventures, Inc.Viking Global Investors

Fountain is a biotech company developing first-in-class therapies for diseases and conditions caused by aging, using in vitro and in vivo screening platforms to identify drug candidates.

BiotechHealthtechLongevitySan Francisco, US

Thomas Rando(Co-founder)Joseph Rodgers(Co-founder)inTom Cheung(Co-founder)inTsang(Chief Business Officer)

Co-investorsKhosla VenturesNan Fung Life SciencesR42 Group

Genomics company building a multi-ancestry biobank and AI-driven analytics for clinical genetic testing and drug discovery.

HealthtechMiami Lakes, US

Carlos D. Bustamante(Executive Officer, Director)inArthur Polk(Executive Officer)Alexander Ioannidis(Director)

BoardWale Ayeni(Director)inMohit Kaushal(Director)Nicholas Katsanis(Director)

Co-investorsCEI VenturesCitta CapitalF-Prime CapitalFounder CollectiveFunction VenturesHelios Digital Ventures+2 more

New York, US

Lee Silver(Director)Anne Morriss(Executive Officer, Director)

BoardAndy Schwab(Director)Jason Epstein(Director)Mara Aspinall(Director)

Co-investors5AM VenturesAlta Partners

Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.

BiotechCambridge, US

Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)Michael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)

Co-investorsCycad Group LLCLux CapitalMC Healthcare VenturesAdvent Life SciencesAuriga PartnersBill & Melinda Gates Foundation+1 more

HealthtechCambridge, US

COLIN HILL(Executive Officer, Director)inIYA KHALIL(Executive Officer)inTHOMAS NEYARAPALLY(Executive Officer)MARK POTTLE(Executive Officer)inCAROL MCCALL(Executive Officer)inBRUCE CHURCH(Executive Officer)in

Co-investorsAmgen VenturesEcho Health Ventures

ARTBIO develops alpha radioligand therapies (ARTs) for cancer treatment, designing target-and-molecule combinations intended to kill tumors while sparing healthy tissue.

BiotechHealthtechMedical DevicesOslo, NO

Roy Larsen(Scientific Founder)Øyvind Bruland(Scientific Founder)Margaret Yu(Chief Medical Officer)Philippe Dasse(Chief Technical Officer)Amra Demirovic(Chief Human Resources Officer)Nicole Hadas(Chief Legal Officer)

Co-investorsB Capital GroupB4 CapitalF-Prime CapitalB CapitalQatar Investment AuthoritySofinnova Ventures+1 more

Holobiome discovers and develops therapies derived from the human gut microbiome, working to translate microbiome science into probiotics and targeted treatments for whole-body health.

AI & Machine LearningBiotechHealthtechLongevityBoston, US

Philip Strandwitz(Co-founder & Director, Chief Executive Officer)inKim Lewis(Co-founder, Director)Mike La Fleur(President, Co-founder, Director)Michael LaFleur(Executive Officer)

BoardJoan LaRovere(Director)inIain Chessell(Director)

Co-investorsAble PartnersBantam GroupHealthtech CapitaliSelect FundPace VenturesService Provider Capital+3 more

Clinical-stage genetic medicines company using human-derived AAV vectors and nuclease-free gene editing for rare diseases.

BiotechBedford, US

Siyamak Rasty(Executive Officer)Albert Seymour(Executive Officer)

BoardSteven Gillis(Director)Arthur Tzianabos(Executive Officer, Director)Kush Parmar(Director)inRichard Gregory(Director)

Co-investors5AM VenturesARCH Venture PartnersOUP (Osage University Partners)Deerfield Management CompanyHBM Healthcare InvestmentsMaverick Ventures+4 more

Hoofprint Biome develops probiotics and natural enzymes based on microbiome engineering to reduce methane emissions from cattle while improving animal health and feed yield.

AgTechBiotechClimate TechCary, US

Scott Collins(Director)inKathryn Polkoff(Executive Officer, Director)inScott Collins, PhD(Founder)in

BoardRodolphe Barrangou(Director)

Co-investorsGood Growth CapitalSOSV

IgGenix is a clinical-stage biotechnology company focused on antibody discovery and development for allergies and immunological diseases.

AI & Machine LearningBiotechHealthtechSouth San Francisco, US

Kari Nadeau(Scientific Co-Founder)

Co-investorsKhosla VenturesAllerfund Ventures, LlcFemHealth VenturesGlobal BrainMedical Incubator Japan K.K.ShangBay Capital LLC+1 more

Immunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development.

AI & Machine LearningBiotechData & InfrastructureNew York City, US

Co-investorsCatalio Capital Management, LPGefen CapitalKoch Disruptive TechnologiesMeron CapitalPerot JainTLV Partners+2 more

IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases.

BiotechHealthtechMedical DevicesWest Nyack, US

Gang Lin(Scientific Founder)Carl Nathan(Scientific Founder)Franck Barrat(Scientific Founder)inMarc Appel(Executive Officer, Director)Lutz Giebel(Director)James Graham(Director)

Co-investorsPathway Bioventures

Khartis is a drug discovery company developing oral therapies for patients with immune-mediated and chronic diseases.

BiotechMedical Devices

Co-investorsForesite CapitalNextech InvestLilly Asia VenturesLongwood Fund

Kytopen develops non-viral gene delivery technology called Flowfect that combines fluid flow with electric fields to deliver payloads such as mRNA, DNA, and CRISPR Cas9 RNP into cells for high-throughput transfection.

BiotechDeep TechHardwareCambridge, US

Cullen Buie(Director)inPaulo Garcia(Executive Officer, Director, Promoter)inMichael Chiu(Director, Executive Officer)in

BoardPaxton Major(Director)Ann DeWitt(Director)inPaul Wotton(Director)

Co-investorsBantam GroupHorizons VenturesMassVenturesSelvedge VentureTBD AngelsTelegraph Hill Partners+2 more

BiotechNew York, US

David Pompliano(Executive Officer)David McElligott(Executive Officer, Promoter)

BoardDavid Schubert(Executive Officer, Promoter)Joel Marcus(Director)Lindsay Rayle(Executive Officer, Promoter)Barbara Dalton(Director)

Co-investorsPfizer Venture InvestmentsAbbVieARCH Venture PartnersDigitalis Ventures

miRecule is a biotechnology company developing therapeutics, with programs focused on oncology.

BiotechHealthtechGaithersburg, US

Anthony D. Saleh(CEO)inDave Lemus(COO/CFO)inAnthony D. Saleh, Ph.D.(CEO)in

Co-investorsBrown and White VenturesPathway BioventuresTachyon Ventures

Molecular Assemblies uses a Fully Enzymatic Synthesis (FES) technology to produce long, pure, and accurate synthetic DNA oligonucleotides, up to 400 bases, without post-synthesis purification.

BiotechDeep TechNew MaterialsSan Diego, US

J. William Efcavitch, Ph.D.(Treasurer and Chief Scientific Officer)Michael J. Kamdar(President, Chief Executive Officer and Secretary)

BoardDavid Hwang(Director)Larry Stambaugh(Chairman of the Board of Directors)John Nicols(Director)Todd Peterson(Director)

Co-investors11.2 CapitalDCVC (Data Collective)iSelect FundArgonautic VenturesCasdin CapitalKeshif Ventures+1 more

A drug discovery company staffed by scientists and industry specialists focused on developing pharmaceutical candidates.

Biotech

Timur Yusufzai(Founder)inAsit Parikh(Chief Executive Officer)in

Co-investorsNextech InvestThird Rock VenturesCasdin CapitalCreacion VenturesGoldman SachsInvus+3 more

Mozart Therapeutics develops protein therapeutics focused on immunology and oncology treatments.

BiotechMedical Devices

Mark Davis(Scientific Co-Founder)K. Christopher Garcia(Scientific Co-Founder)Calvin Kuo(Scientific Co-Founder)Katie Fanning(President & Chief Executive Officer)in

Co-investorsARCH Venture PartnersJDRF T1D FundMRL Ventures FundOno Venture Investment, Inc.Pfizer Venture InvestmentsSofinnova Partners+3 more

Neurona Therapeutics is a clinical-stage biotherapeutics company developing allogeneic neural cell therapies to treat chronic disorders of the nervous system.

BiotechDeep TechHealthtechSouth San Francisco, US

Cory Nicholas(Executive Officer, Director, Promoter)inJames Stutz(Chief Financial Officer and Chief Business Officer)inCatherine Priest(Chief Development Officer)inGautam Banik(Chief Technology Officer)inEduardo Dunayevich(Chief Medical Officer)inArnold Kriegstein(Director)

Co-investorsBerkeley FrontierIaso VenturesThe Column GroupYsios CapitalFidelity InvestmentsLYFE Capital+7 more

Overt Bio develops cell therapies that link genes to immune functions using genome-scale discovery platforms.

AI & Machine LearningBiotechMedical DevicesNew York, US

Dr. Legut(Co-Founder and CEO)Dr. Sanjana(Co-Founder)Mateusz Legut(Executive Officer, Director)Neville Sanjana(Director)Mat Legut(Founder)in

BoardVasudev Bailey(Director)in

Co-investorsArtis VenturesCivilization Ventures Management, LlcFusionHAWKTAILWingGaingels+1 more

Ozette runs a vertically integrated, AI-enabled lab and platform that generates high-dimensional spectral cytometry data and analyzes it to produce reproducible biomarker endpoints for clinical trials.

AI & Machine LearningBiotechHealthtech

Greg Finak(Founder)inEvan Greene(Co-founder)inAli Ansary(Co-founder)in

Co-investorsAllen Institute for AI (AI2) IncubatorAlpha Ascent Ventures LlcM12 (Microsoft's Venture Fund)Madrona Venture GroupOCV Partners

Seattle, US

Ali Ansary(Executive Officer, Director)Greg Finak(Director)

BoardMatt McIlwain(Director)

Co-investorsMadrona Venture GroupOCV Partners

BiotechNew York, US

Brian O'Callaghan(Executive Officer, Director)David Renas(Executive Officer)Albert Yu(Executive Officer, Promoter)David McElligott(Executive Officer, Promoter)

BoardSteve Gillis(Director)Joel Marcus(Director)

Co-investors180 Degree CapitalAbbVieARCH Venture PartnersJohnson & Johnson Innovation – JJDCPfizer Venture Investments

Pheast Therapeutics develops immunotherapies targeting cancer, building on foundational research from Stanford's stem cell research institute.

BiotechHealthtechMedical DevicesRedwood City, US

Irv Weissman(Cofounder, Scientific Advisor, Board Director)Ravi Majeti(Cofounder, Scientific Advisor, Board Observer)Amira Barkal(Principal Founder, Scientific Advisor, Board Director)inRoy Maute(Cofounder & Chief Executive Officer)in

BoardJacob Vogelstein(Director)Steven Gillis(Director)in

Co-investorsARCH Venture PartnersCatalio Capital Management, LPCatalio Capital Management

HealthtechNew York, US

ASA ABELIOVICH(Executive Officer, Director)in

BoardPETER THOMPSON(Director)inMONA ASHIYA(Director)inCARL GORDON(Director)in

Co-investorsEcoR1 CapitalOrbiMedRA Capital

Proxima develops AI-powered gaming experiences and infrastructure, with a focus on embodied AI agents and applied AI systems for interactive entertainment.

AI & Machine LearningGamingSan Francisco, US

Ran Mo(Founder)in

Co-investorsKonvoy VenturesProgressionAIX VenturesBalderton CapitalBayern KapitalBraidwell+9 more

BiotechNew York, US

Joseph P. Vacca, Ph.D(President and Treasurer)

BoardMichael Foley, Ph.D.(Director)

Co-investorsTaiho Ventures, LLCVersant Ventures

Remedy Plan is a biopharmaceutical company developing drugs that target NAMPT, an essential enzyme dysregulated in more than 20 diseases including cancer.

BiotechHealthtechRockville, US

Gregory Plan Crimmins(Executive Officer, Director)

Co-investors20/20 HealthCare Partners LLCSchooner Capital

BiotechSeattle, US

Sanford Markowitz(Director)Thong Le(Executive Officer, Director, Promoter)David Schubert(Executive Officer, Promoter)James Sullivan(Director)Lindsay Rayle(Executive Officer, Promoter)Tadataka Yamada(Director)

Co-investorsCWRU Technology VenturesARCH Venture Partners

AgTechHarrisonburg, US

Barbara Kite(Vice President of Finance and Human Resources)Steve Wright(Vice President of Sales and Purchasing)Robert Hoffman(Chief Technology Officer)Philip Karp(Chief Operating Officer)Ilir Cela(Executive Officer)Timothy Heydon(President and Chief Executive Officer)

Co-investorsAdvantage Capital PartnersArborview CapitalDns CapitalMiddleland CapitalS2G InvestmentsXPV Water Partners

Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets.

AI & Machine LearningBiotechDeep TechDurham, US

Mark A. Hallen(Executive Officer, Director)inMarcel Frenkel(Executive Officer, Director)Damien Petty(Director)Jia Wei Xu(Director)

Co-investorsCape Fear BioCapitalDFJ DragonFundDraper AssociatesDuke Capital PartnersHatteras Venture PartnersHatteras+2 more

PartnerJoel S. Marcus· solo GP

BiotechCambridge, US

James G. McArthur(Executive Officer)Abraham N. Ceesay(Executive Officer)Christoph M. Adams(Executive Officer, Director)

BoardMette Kirstine Agger(Director)David Mott(Director)Sandip Agarwala(Director)

Co-investorsLongitude CapitalLundbeckfonden VenturesNew Enterprise Associates (NEA)

Ventus AI is an enterprise automation platform offering AI agents ("AI teammates") that operate inside existing systems—desktop apps, web portals, and legacy software—without API integrations to automate complex business workflows, handling MFA, CAPTCHAs, and phone calls.

AI & Machine LearningEnterprise SoftwareHealthtechCasa Grande

Maran Vedamanikam(CEO and Manager)

Co-investorsSamsung NextAndreessen HorowitzWndrCoBiotechnology Value FundCasdin CapitalFonds de solidarité FTQ+5 more

BiotechNew York, US

BoardIsaac Blech(Vice Chairman)William A. Haseltine(Director)Roger Pomerantz(Director)Robert Ruffolo(Director)

Co-investorsAdjuvant CapitalFounders FundJJDCJohnson & Johnson Innovation – JJDC

BiotechHealthtechDurham, US

Xiling Shen(Executive Officer, Director, Promoter)David Shiaowen(Director)William Roy Smythe(Executive Officer, Director)

BoardAlaa Halawa(Director)John de Koning(Director)

Co-investorsAlix VenturesCatalio Capital ManagementEQT Life SciencesFelicis VenturesMC Healthcare VenturesMubadala Capital+2 more

ZymoChem develops bio-based materials using proprietary Carbon Conserving (C2) microbes that convert renewable feedstocks into high-value materials with increased yields.

BiotechCircular EconomyClimate TechNew MaterialsSan Leandro, US

Harshal Chokhawala(Founder & CEO)in

Co-investorsAccelr8Breakout LabsBreakout VenturesCavallo VenturesDudley FundFreshTracks Capital+7 more